Fox Chase Cancer Center Joins Onclive® in Strategic Alliance Partnership Program

Article

OncLive® and Fox Chase Cancer Center, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center that is part of the Temple University Health System in Philadelphia, announced that they have joined forces to raise awareness of significant oncology research and clinical practice news through OncLive's Strategic Alliance Partnership program.

PLAINSBORO, NJ (Feb. 3, 2015) — OncLive® and Fox Chase Cancer Center, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center that is part of the Temple University Health System in Philadelphia, announced today that they have joined forces to raise awareness of significant oncology research and clinical practice news through OncLive’s Strategic Alliance Partnership program. Through the new partnership, OncLive’s editorial and marketing teams will work with Fox Chase to highlight important oncology research and clinical practice news from the Center.

“We are honored to partner with Fox Chase Cancer Center to increase awareness of the Center’s cutting-edge work on cancer,” said Mike J. Hennessy Jr., senior vice president, oncology & specialty pharmacy. “The more we get the word out about new developments in cancer care, the more likely we are to keep finding better ways to treat, prevent or even cure this disease.”

Fox Chase’s rank as an NCI-designated Comprehensive Cancer Center makes it one of only 41 centers in the country to hold this highest level of designation. The doctors at Fox Chase treat more cases of rare and common cancers than other hospitals — and research shows that more experience is linked to better outcomes. In addition, Fox Chase physicians and researchers are leaders in setting new guidelines for breakthrough medicine and comprehensive care.

“Fox Chase is committed to pioneering discoveries that advance new approaches to cancer treatment, prevention, detection and survivorship,” said Richard I. Fisher, MD, president and CEO of Fox Chase. “We look forward to working with OncLive to share new developments at Fox Chase with the healthcare professional and patient communities.”

The alliance makes it possible, via OncLive’s suite of print and online publications, to offer healthcare professionals and patients direct, timely updates on key developments in cancer treatment and research happening at Fox Chase and more than 30 other leading cancer centers, nursing schools and physician groups around the country.

About OncLive


OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News and Contemporary Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, based in Plainsboro, N.J. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURE magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers and advocacy groups. To learn more, please visit www.OncLive.com.

About Fox Chase Center

Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received Magnet status for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. For more information, visit Fox Chase’s website at http://foxchase.org/ or call 1-888-FOX CHASE (1-888-369-2427).

###

Media Contact for OncLive:

Becky Taylor, 609.240.6886, becky@btaylorpa.com

Related Videos
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center